Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history.

January 17, 2025

Vol.51 No.02

By Dan Theodorescu, Robert A. Figlin, Howard M. Sandler and Joan August

As fire encroached, City of Hope prepared to evacuate its Duarte campus

On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest.

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.

December 06, 2024

Vol.50 No.45

Health Equity

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.

November 22, 2024

Vol.50 No.44

By McKenzie Prillaman

In Brief

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.

November 22, 2024

Vol.50 No.44

Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s

YOU MAY BE INTERESTED IN

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

As fire encroached, City of Hope prepared to evacuate its Duarte campus

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

Renew today!

Subscriber content

Never miss an issue!

Login